ライフサイエンスコーパス: PHN

1 PHN occurred in 26 vaccinated men (6.0%) versus 25 unvac

2 PHN-associated VZV significantly increased sodium curren

3 PHN-associated VZV sodium current increases were therefo

4 e vaccine at age 50 years, 25 HZ cases and 1 PHN case could be prevented.

5 enty VZV isolates were studied blind from 11 PHN and 9 non-PHN subjects.

6 s clear whether the vaccine protects against PHN among patients who develop HZ despite previous vacci

7 VE against PHN was 0.59 (95% CI 0.21-0.79).

8 perceived a high level of burden from HZ and PHN and generally favored the HZ vaccine.

9 The incidence and severity of HZ and PHN are highest in older adults.

10 , physicians who strongly agreed that HZ and PHN cause significant burden were more likely to recomme

11 nd FM physicians strongly agreed that HZ and PHN caused a significant burden of disease.

12 ficantly reduced the morbidity due to HZ and PHN in older adults.

13 The incidence and severity of HZ and PHN increase with age in association with an age-related

14 e a crucial innovation for preventing HZ and PHN.

15 on would protect older adults against HZ and PHN.

16 Vaccine efficacy against incident zoster and PHN has been demonstrated in clinical trials, but effect

17 fectiveness (VE) against incident zoster and PHN in a general population-based setting.

18 dence rates and hazard ratios for zoster and PHN were determined in vaccinated and unvaccinated indiv

19 essed 2 and 7 days (NTS), or 10 and 30 days (PHN) later.

20 y-one percent of patients with HZO developed PHN.

21 famciclovir and placebo groups who developed PHN; the impact of famciclovir treatment on the duration

22 the cinchona alkaloid-derived catalyst DHQD-PHN was clarified by catalyst conformation studies with

23 stereochemical model to rationalize how DHQD-PHN differentiates the two enantiotopic carbonyl groups

24 ree cinchona alkaloid catalysts, namely DHQD-PHN, DHQD-MEQ, and DHQD-CLB, based on calculations of ou

25 Thirty vaccinated women (4.2%) experienced PHN, compared with 75 unvaccinated women (10.4%), with a

26 or uveitis were found to be risk factors for PHN.

27 as higher and better preserved over time for PHN and HZ-associated hospitalizations than for communit

28 In the primary analysis, VE for PHN was 57% (95% CI: 52%-61%) and 45% (95% CI: 36%-53%)

29 tive in scenarios where PHN risk was higher, PHN duration longer, or antiviral shortening of PHN grea

30 th Nav1.6 and Nav1.7 mRNA but not Nav 1.8 in PHN virally infected cells.

31 rom actin at the onset of podocyte injury in PHN.

32 cation (NC(Ca-ATP)) channels are involved in PHN.

33 to a more dispersed and clustered pattern in PHN.

34 accination is associated with a reduction in PHN.

35 CI) causes progressive hemorrhagic necrosis (PHN), a poorly understood pathological process character

36 ic serum (NTS) or passive Heymann nephritis (PHN) was induced in Sprague-Dawley rats.

37 nous nephropathy (passive Heymann nephritis (PHN)), complement C5b-9-induced proteinuria was associat

38 of proteinuria in passive Heymann nephritis (PHN), a rat model of human membranous nephropathy.

39 Post-herpetic neuralgia (PHN) is the most significant complication of herpes zost

40 nsequences, notably post-herpetic neuralgia (PHN).

41 rpes zoster (HZ) and postherpetic neuralgia (PHN) cause significant morbidity in older adults.

42 rrent treatments for postherpetic neuralgia (PHN) have led to the investigation of localised, non-sys

43 Postherpetic neuralgia (PHN) is a common complication of shingles that manifests

44 Postherpetic neuralgia (PHN) is a syndrome of often intractable neuropathic pain

45 vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it

46 antiviral efficacy, postherpetic neuralgia (PHN) risk, and other illness parameters.

47 tion are at risk for postherpetic neuralgia (PHN), a painful and long-lasting complication.

48 llness, incidence of postherpetic neuralgia (PHN), and incidence of HZ were assessed for the STPS pop

49 rpes zoster (HZ) and postherpetic neuralgia (PHN), intentions for recommending the HZ vaccine, and pe

50 litating pain called postherpetic neuralgia (PHN), which can last for months after the disappearance

51 painful condition of postherpetic neuralgia (PHN), which has been difficult to treat because the unde

52 t on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting after rash he

53 many of whom develop postherpetic neuralgia (PHN).

54 lmic zoster (OZ) and postherpetic neuralgia (PHN).

55 and chronic pain, or postherpetic neuralgia (PHN).

56 group 1), zoster and postherpetic neuralgia (PHN; group 2), or no history of zoster (group 3) reveale

57 provide insight into the development of new PHN therapies.

58 tes were studied blind from 11 PHN and 9 non-PHN subjects.

59 tude in the cell line when compared with non-PHN VZV, wild-type (Dumas) or vaccine VZV strains ((POka

60 ion into the posterior hypothalamic nucleus (PHN).

61 Sites using public health nurses (PHNs) started more high-risk TST(-) contacts on presumpt

62 Four days after immunization, 58% of PHN rats had mild proteinuria.

63 decline of total nephrin on days 4 and 7 of PHN as well as a reduction in the actin-associated fract

64 y endothelium are critical to development of PHN and constitute a major target for therapy in SCI.

65 of famciclovir treatment on the duration of PHN, while controlling for significant covariates; and t

66 -69.1%; P<.001) and reduced the incidence of PHN by 66.5% (95% CI, 47.5%-79.2%; P<.001).

67 50.1%, vaccine efficacy for the incidence of PHN decreased from 66.5% to 60.1%, and vaccine efficacy

68 The incidence of PHN was compared between vaccinated and unvaccinated -pa

69 The secondary end point was the incidence of PHN.

70 iva is the outcome of zoster, independent of PHN.

71 HZ to prevent PHN, and the intractability of PHN, the advent of the HZ vaccine appears to be a crucia

72 iated with the development or persistence of PHN at 6, 12, or 26 weeks.

73 remia and the development and persistence of PHN.

74 ignificant covariates; and the prevalence of PHN at monthly intervals from 30 to 180 days after enrol

75 reduces both the duration and prevalence of PHN.

76 ccination is associated with a lower risk of PHN in women but not in men.

77 duration longer, or antiviral shortening of PHN greater.

78 imitation (P limitation) or during growth on PHN compared with their rates in the cultures with Pi we

79 eins responding to P limitation or growth on PHN was 30 to 40% of the cells' total mass.

80 imitation with those responding to growth on PHN, one can speculate which proteins are likely involve

81 ere VZV infections but have little impact on PHN.

82 Demographic data and information on PHN were collected electronically.

83 Pi were classified as belonging to the PL or PHN stimulon, respectively.

84 tization in comparison with phenylhydrazine (PHN) derivatization.

85 tate growth in media containing phosphonate (PHN) as the sole P source was examined by two-dimensiona

86 ficulty of adequately treating HZ to prevent PHN, and the intractability of PHN, the advent of the HZ

87 pain severity are risk factors for prolonged PHN.

88 The Pediatric Heart Network's (PHN) single ventricle reconstruction (SVR) trial compare

89 The PHN stimulon was smaller: it included 257 proteins; 227

90 On day 7, the PHN rats were severely proteinuric, and most slit diaphr

91 New data from the PHN are now beginning to show equipoise for the two pall

92 NPY-evoked cardiovascular responses from the PHN by determining the rank order of potency of several

93 r respective cardiovascular changes from the PHN with NPY stimulating the Y(1) receptor.

94 Y(1) receptor antagonist BIBP 3226 into the PHN prior to NPY completely blocked the cardiovascular r

95 tide YY (PYY) or CCh microinjection into the PHN.

96 been proposed to be a factor contributing to PHN.

97 considered cost effective in scenarios where PHN risk was higher, PHN duration longer, or antiviral s

98 nfection in vitro study to determine whether PHN-associated VZV isolates induce changes in sodium ion

99 pain and sleep interference associated with PHN.

100 one application of NGX-4010 in patients with PHN.

101 tivated in glomeruli isolated from rats with PHN.

102 ts with a history of zoster, with or without PHN (21 [67%] of 32 subjects in groups 1 and 2), than in